In many cases, patients may undergo an initial series of treatments spaced out over a few weeks to address immediate concerns, such as boosting antioxidant levels or enhancing detoxification processes
Mechanistically, GLP-1RAs suppress innate immune responses by downregulating pro-inflammatory cytokines such as IL-1 and IL-6, while upregulating adiponectin, an anti-inflammatory adipokine [361, 381, 382]
E., Maryanoff, C
GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) commonly cause headaches during initial weeks or after dose escalation due to altered gastric emptying, hydration changes, and metabolic adjustments
But its reassuring to see that with the highest level of evidence, theres no signal for concern.